Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis [PDF]
Frontiers in PediatricsIntroductionAcute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes ...
Zheng Li +3 more
doaj +3 more sources
Molecular Therapy - Oncolytics, 2023 CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both CD33 ...
Marco L Davila +2 more
exaly +4 more sources
CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells
Nanomaterials, 2021 Acute myeloblastic leukemia (AML) is a disease with a high rate of relapse and drug resistance due to the remaining leukemic stem cells (LSCs). Therefore, LSCs are specific targets for the treatment of leukemia.
Songyot Anuchapreeda +2 more
exaly +4 more sources
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation [PDF]
Haematologica, 2022 The outcome of patients with acute myeloid leukemia remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen receptors or bispecific T-cell engagers targeting CD123 are actively being explored in preclinical
Abishek Vaidya +9 more
doaj +2 more sources
Prognostic impact of CD123 overexpression on the outcome of pediatric acute myeloid leukemia [PDF]
Frontiers in OncologyBackground and aimsDespite advances in acute myeloid leukemia (AML) therapy, outcomes remain poor. CD123 overexpression influences proliferation and enhanced survival of leukemic cells. Its impact on the outcome is still debatable.
Mona Mohammed +13 more
doaj +2 more sources
Leukemia Research Reports, 2020 This study was designed to assess the significance of interleukin-2 receptor (CD25) and inteleukin-3 receptor (CD123) expression in cytogenetically normal acute myeloid leukemia (CN-AML) patients.
Salah Aref +2 more
exaly +3 more sources
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Molecular Therapy - Oncolytics, 2020 Chimeric antigen receptor T cells (CAR-T) targeting CD19 or B cell maturation antigen (BCMA) are highly effective against B cell malignancies. However, application of CAR-T to less differentially expressed targets remains a challenge due to lack of tumor-
Anja Feldmann +2 more
exaly +3 more sources
Frontiers in Molecular Biosciences, 2022 Background: Altered basophil identification markers have been discovered to associate with allergic asthma (AA) in recent years. However, little is known about the expression of basophil markers in blood granulocytes.Aim: To parallel test blood basophils
Hua Xie +11 more
doaj +1 more source
Analyses of the clinical and immunological characteristics of patients with lupus erythematosus
Indian Journal of Dermatology, 2022 Background: Lupus erythematosus (LE) is a broad-spectrum, heterogeneous disease. At one end of the spectrum is the cutaneous LE (CLE) without systemic involvement, and at the other end is the systemic LE (SLE) with multisystem involvement.
Min Deng +4 more
doaj +1 more source
Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts [PDF]
Cell Journal, 2021 Objective: The clinical studies of acute myeloid leukaemia (AML) revealed that antigen escaping variants cause cancer recurrence even after treatment with chimeric antigen receptor (CAR)-T cells that target a single tumour antigen.
Ali Ghamari +4 more
doaj +1 more source